Cero Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cell therapy product candidates. The company has not generated revenue and does not expect product sales in the foreseeable future, reflecting its pre-commercial stage. Its business model is centered on advancing preclinical and clinical programs toward regulatory approval, with any future revenue expected to come from product commercialization, licensing, milestones, or R&D services. Because it is still funding development and public-company operations, CERo currently depends on external financing rather than operating cash flow.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueExperimental therapeutic candidates being advanced through preclinical and clinical development.
Potential future R&D services and collaboration work tied to development programs.
Out-licensing of product candidates and related rights to third parties.
Contingent future payments tied to development, approval, or product sales outcomes.
Customers
CERo does not currently sell commercial products, so it does not yet have a traditional customer base. Its near-term counterparties are investors, service providers, and potential development partners that support financing and drug development activities. If its programs progress, the company’s eventual customers would likely include healthcare providers, hospitals, and patients through approved therapeutic products, while licensing partners could become an important source of non-product revenue. The company also references future revenue possibilities from R&D services, milestones, and royalties, which implies a business model that may combine direct commercialization with partnering.
Equity investors and financing counterparties that fund the company while it develops product candidates and maintains listing compliance.
CROs, consultants, and other service providers that support preclinical work, clinical planning, and public-company administration.
Biopharma partners that could license product candidates or collaborate on development in exchange for upfront, milestone, or royalty payments.
Hospitals, physicians, and patients that would use approved therapies if the company successfully commercializes a product.
Strategy
CERo’s immediate strategic priority is to fund and advance its preclinical and clinical development programs toward regulatory approval. Management explicitly states that most available cash is intended for development work and public-company compliance costs, which is typical for a clinical-stage biotech with no revenue. The company is also using equity lines, private placements, and warrant exercises to extend liquidity, indicating that financing execution is central to strategy. Longer term, CERo appears to be positioning itself for either direct commercialization or partnering, with future revenue expected from product sales, licensing, milestones, or royalties if development succeeds.
The company has no revenue and needs financing to support ongoing research, clinical work, and operating overhead.
Regulatory progress is the main path to any future product revenue or partnering value.
Licensing or milestone-based collaborations could create non-product revenue before full commercialization.
Geography
CERo is headquartered in the United States and its reported business activity is centered on U.S. capital markets, U.S. regulatory oversight, and U.S.-based development operations. The company has not disclosed meaningful country-level revenue because it has not recognized revenue from any source. Its exposure is therefore primarily domestic, but it still faces global supply-chain and tariff-related risks common to biotech companies that rely on imported materials, outsourced research, or future manufacturing inputs. As the company advances toward clinical development and possible commercialization, geography will matter more through trial sites, manufacturing partners, and regulatory pathways.
Risks
The company’s largest risk is financing risk: it has no revenue, expects losses to continue, and states that current cash will not fund operations for 12 months. That makes CERo dependent on repeated equity raises, which can be dilutive and may not be available on favorable terms. Clinical-stage biotech also faces high development risk, because product candidates may fail in preclinical or clinical testing or may never obtain regulatory approval. In addition, the company is exposed to public-company compliance risk, Nasdaq listing requirements, and broader biotech industry risks such as competition, manufacturing scale-up, reimbursement uncertainty, and changes in regulatory or tax policy.
- Liquidity and going-concern dependence on external financingImpact: CriticalLikelihood: High
The company has no revenue and states that existing cash will not fund operations for 12 months, so it must raise capital to continue development.
Exposure: Operating runway and dilution risk
- Clinical and regulatory development failureImpact: HighLikelihood: High
The business depends on successful preclinical and clinical progress and eventual regulatory approval, which are inherently uncertain.
Exposure: Pipeline value and future revenue potential
- Dilution from equity financings and preferred stock structuresImpact: HighLikelihood: High
Recent financings included common stock, pre-funded warrants, preferred stock, and conversion features that can materially change ownership and earnings per share.
Exposure: Shareholder dilution and capital structure complexity
- Nasdaq continued listing complianceImpact: MediumLikelihood: High
The company has had to manage stockholders’ equity thresholds and other listing requirements, which can affect market access and investor confidence.
Exposure: Listing status and financing access
Accounting
Judgemental itemsThese non-cash charges materially reduce net loss attributable to common stockholders and can distort comparability across periods.
Impact: Affects EPS and common shareholder loss attribution
The company uses Black-Scholes and other judgmental inputs to measure equity awards, which can materially affect operating expenses.
Impact: Affects reported R&D and G&A expense
Complex equity-linked instruments may require remeasurement and can create gains or losses unrelated to core operations.
Impact: Affects non-operating income/expense and volatility
The investment in Stella Diagnostics, Inc. is subject to impairment and fair value adjustments under the measurement alternative.
Impact: Affects earnings if value changes are recognized
Similar listed companies
Publicly listed companies with a comparable business focus.
Celularity Inc
CELU · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Last updated: 24/09/2026